Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > July/August 2007 - Volume 30 - Issue 4 > An Open-Label Trial of Escitalopram in the Treatment of Path...
You could be reading the full-text of this article now...
If you have access to this article through your institution, you can view this article in OvidSP.
Clinical Neuropharmacology:
July/August 2007 - Volume 30 - Issue 4 - pp 206-212
doi: 10.1097/wnf.0b013e31803d357f
Original Articles

An Open-Label Trial of Escitalopram in the Treatment of Pathological Gambling

Black, Donald W. MD; Shaw, Martha BA; Forbush, Kelsie T. MA; Allen, Jeff PhD

Collapse Box

Abstract

Background: The effectiveness and tolerability of escitalopram was tested in the treatment of pathological gambling (PG).

Method: Nondepressed outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG received flexibly dosed escitalopram in a prospective, 10-week, open-label trial after a 2-week observation period. Subjects were evaluated at baseline and at 2-week intervals for assessment of gambling behavior, mood symptoms, and adverse experiences. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale modified for PG. Secondary efficacy measures included the Clinical Global Impression (CGI) Improvement and Severity Scales, a patient self-rated global rating, the Sheehan Disability Scale, and the Timeline Follow Back.

Results: Nineteen subjects (12 men and 7 women) had at least 1 postbaseline visit and were included in the analysis; 16 subjects (84%) completed the protocol. Significant improvement was found in all measures, including the Yale-Brown Obsessive-Compulsive Scale modified for PG, both CGI Scales, a patient self-rated global scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Checklist, the Hamilton Depression Rating Scale, and all 3 Sheehan Disability Scale subscales. Fourteen subjects (73.7%) were considered responders (ie, achieved "much" or "very much" improvement on the CGI). Few adverse experiences were reported.

Conclusion: The results suggest that escitalopram is well tolerated and may be effective in the treatment of PG.

© 2007 Lippincott Williams & Wilkins, Inc.

Login




Help

Forgot Password?

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.